Portola Pharmaceuticals to Announce First Quarter 2014 Financial Results and Host Conference Call on Monday, May 12, 2014
05 Mai 2014 - 2:00PM
Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it
will host a webcast and conference call to discuss the Company's
financial results for the quarter ended March 31, 2014 and provide
a general business overview on Monday, May 12, 2014 at 4:30 p.m.
Eastern Time (1:30 p.m. Pacific Time).
Conference Call Details
To access the live conference call, please dial (866) 515-2912
from the U.S. and Canada, or +1(617) 399-5126 internationally, and
use the passcode 75374493. Please dial in 10 minutes prior to the
start of the call.
To access the live and subsequently archived webcast of the
conference call, go to the Investor Relations section of the
company's website at http://investors.portola.com. Please connect
to the website at least 15 minutes prior to the call to allow for
any software download that may be necessary. A replay of the
webcast will be available on the Company's website for 30 days
following the live event.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company
developing product candidates that have the potential to represent
significant advances in the fields of hematology and inflammation.
The Company is advancing its three wholly-owned hematology programs
using novel biomarker and genetic approaches that may increase the
likelihood of clinical, regulatory and commercial success of its
first-in-class therapies. Portola's partnered program is focused on
developing selective Syk inhibitors for inflammatory
conditions.
Betrixaban
Portola's wholly-owned, oral, once-daily Factor Xa inhibitor
betrixaban is being evaluated in a biomarker-based Phase 3 study
for "hospital to home" prophylaxis of venous thromboembolism (VTE)
in acute medically ill patients. Betrixaban's properties may be
particularly suited to potentially demonstrate efficacy without
significantly increasing bleeding in this patient population.
Currently, there is no anticoagulant approved for extended-duration
VTE prophylaxis in acute medically ill patients.
Andexanet Alfa
Portola's second product candidate in the area of thrombosis,
andexanet alfa, has the potential to be a first-in-class reversal
agent to reverse the effects of Factor Xa inhibitors in patients
who suffer a major bleeding episode or who require emergency
surgery. Portola has entered into clinical collaboration agreements
with all of the manufacturers of direct Factor Xa inhibitors,
including Bristol-Myers Squibb and Pfizer (Eliquis® [apixaban]),
Bayer HealthCare and Janssen Pharmaceuticals (XARELTO®
[rivaroxaban]), and Daiichi Sankyo (edoxaban), while retaining all
commercial rights to andexanet alfa. Andexanet alfa has been
designated as a Breakthrough Therapy by the U.S. Food and Drug
Administration.
Cerdulatinib* (PRT2070)
Portola's product candidate in the area of hematologic cancer,
cerdulatinib, is an orally available molecule that uniquely
inhibits two validated tumor proliferation pathways -- spleen
tyrosine kinase (Syk) and janus kinase (JAK). It is currently being
studied in patients with leukemias or lymphomas with a focus on
genetically-defined subtypes, as well as in patients who have
failed therapy due to relapse or acquired mutations.
For more information, visit www.portola.com and follow the
Company on Twitter @Portola_Pharma.
*Cerdulatinib is a proposed International Nonproprietary Name
(pINN).
CONTACT: Investor Contact:
Alexandra Santos
Portola Pharmaceuticals
ir@portola.com
650.246.7239
Media Contact:
Joey Fleury
BrewLife
jfleury@brewlife.com
415.946.1090
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024